Clinical trials: Tislelizumab, open to volunteers
NSCLC, Tislelizumab
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in…
- Conditions
- NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
- Trial name
- TitAN (NCT07089199)
- Testing
- neoadjuvant therapy, Surgery, Adjuvant therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Qilu Hospital of Shandong University
Borderline Resectable Carcinoma, Unresectable Cancer
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality.
- Conditions
- Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
- Trial name
- ILDR-03 (NCT07339488)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Chuangzhen Chen
Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially…
- Conditions
- Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
- Trial name
- BEACON-Lung (NCT07561983)
- Testing
- Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
ESCC, Tislelizumab
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis.
- Conditions
- ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
- Trial name
- NCT07531979
- Testing
- Tislelizumab, Becotatug Vedotin, Cisplatin
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Renal Pelvic Carcinoma, Tislelizumab
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
This study is designed as an open-label, single-arm, single-center, phase II clinical trial, aiming to evaluate the efficacy of nephron-sparing treatment combining Tislelizumab and Nab-Paclitaxel for HER-2 expressing renal pelvic…
- Conditions
- Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing
- Trial name
- NCT07233252
- Testing
- Nab-paclitaxel, Tislelizumab, endoscopic intervention
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
NSCLC, Tislelizumab
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy…
- Conditions
- NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
- Trial name
- NCT07198217
- Testing
- SBRT combined with Tislelizumab followed by Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zibo Municipal Hospital
Ureteral Cancer, Neoadjuvant Therapy
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
This study is designed as an open-label, single-arm, single-center, phase II clinical trial, aiming to evaluate the efficacy and safety of neoadjuvant Tislelizumab combined with Nab-Paclitaxel followed by distal ureterectomy for…
- Conditions
- Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
- Trial name
- NCT07125547
- Testing
- PD-1 inhibitior, Nab-paclitaxel, distal ureterectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Second Hospital
NSCLC, Tislelizumab
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by…
- Conditions
- NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
- Trial name
- NCT07085182
- Testing
- SBRT combined with Tislelizumab followed by Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zibo Municipal Hospital
Surufatinib, Tislelizumab
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with…
- Conditions
- Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy, Consolidation Therapy
- Trial name
- NCT07086456
- Testing
- Surufatinib, Tislelizumab, Concurrent Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepatocellular Carcinoma, Lenvatinib
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE
- Trial name
- NCT05920863
- Testing
- TACE, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
MSI-H Colorectal Cancer, Tislelizumab
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with…
- Conditions
- MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin, Capecitabine
- Trial name
- NCT05841134
- Testing
- Tislelizumab
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University